The Fas counterattack in vivo: Apoptotic depletion of tumor- infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5669-5675

  Bennett, Michael W ^a   O'Connell, Joe ^a   O'Sullivan, Gerald C ^b   Brady, Ciaran ^a   Roche, Desmond ^a   Kevin Collins, J ^a   Shanahan, Fergus ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS LIGAND;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS;

EID: 0032103027     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Blot, W. J., S. S. Devesa, R. W. Kneller, and J. F. Fraumeni, Jr. 1991. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287.
2. Walsh, T. N., N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T. P. Hennessy. 1996. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335:462.
3. Hennessy, T. P. 1996. Cancer of the esophagus. Postgrad. Med. J. 72:458.
4. O'Sullivan, G. C., A. R. Corbett, F. Shanahan, and J. K. Collins. 1997. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J. Immunol. 157:4717.
5. O'Mahony, A. M., G. C. O'Sullivan, J. O'Connell, T. G. Cotter, and J. K. Collins. 1993. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J. Immunol. 151:4847.
6. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1997. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 3:294.
7. Mountz, J. D., T. Zhou, H. Bluethmann, J. Wu, and C. K. Edwards. 1994. Apoptosis defects analyzed in TcR transgenic and Fas transgenic lpr mice. Int. Rev. Immunol. 11:321.
8. Alderson, M. R., T. W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. A. Schooley, R. G. Goodwin, C. A. Smith, F. Ramsdell, and D. H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71.
9. Daniel, P. T., and P. H. Krammer. 1994. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152:5624.
10. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189.
11. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
12. Stuart, P. M., T. S. Griffith, N. Usui, J. Pepose, X. Yu, and T. A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396.
13. Korbutt, G. S., J. F. Elliott, and R. V. Rajotte. 1997. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46:317.
14. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 270:109.
15. Arai, H., S. Y. Chan, D. K. Bishop, and G. J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843.
16. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
17. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for rumor immune escape. Science 274:1363.
18. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
19. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp. D. R. Green, and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007.
20. Saas, P., P. R. Walker, M Hahne, A.-L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. G. Van Meir, N. de Tribolet, J. Tschopp, and P.-Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
21. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420.
22. Rockett, J. C., S. J. Darnton, J. Crocker, H. R. Matthews, and A. G. Morris. 1996. Lymphocyte infiltration in esophageal carcinoma: lack of correlation with MHC antigens, ICAM-1, and tumor stage and grade. J. Clin. Pathol. 49:264.
23. Ropponen, K. M., M. J. Eskelinen, P. K. Lipponen, E. Alhava, and V.-M. Kosma. 1997. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 182:318.
24. Mulder, W. M. C., E. Bloemena, M. J. Stukart, J. A. Kummer, J. Wagstaff, and R. J. Scheper. 1997. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113.
25. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet affograft. Proc. Natl. Acad. Sci. USA 94:3943.
26. Kang, S.-M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738.
27. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
28. Lau, H. T., and C. J. Stoeckert. 1997. FasL: too much of a good thing? Nat. Med. 3:727.
29. Zhang, H., Y. Yang, J. L. Horton, E. B. Samoilova, T. A. Judge, L. A. Turka, J. M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100:1951.
30. Nagata, S. 1996. Fas figand and immune evasion: expression of a death factor by tumor cells may explain their escape from immune attack. Nat. Med. 2:1306.
31. Ohbu, M., M. Saegusa, N. Kobayashi, H. Tsukamoto, H. Mieno, A. Kakita, and I. Okayasu. 1997. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 79:1287.